ANTI-SARS-COV-2 ANTIBODY LEVELS AFTER FOURTH DOES OF COVID-19 VACCINE IN PATIENTS WITH END-STAGE RENAL DISEASE

Như Nghĩa Nguyễn1,, Huỳnh Ngọc Tân Mai1, Minh Giàu Huỳnh2
1 Can Tho University of Medicine - Pharmacy
2 Giong Rieng District Medical Center

Main Article Content

Abstract

December 2019, seriously affecting the health of everyone, including patients with chronic kidney disease. By 2021, Vietnam has implemented vaccination against Covid-19, and there have been some initial studies evaluating antibody against SARS-CoV-2 virus after vaccination. However, most of the research was conducted on normal people, 1 to 2 doses after vaccination. Objectives: to evaluate levels of antibodies targeting the receptor binding protein (anti-RBD) after 4th dose of Covid-19 vaccine and some related factors in chronic kidney disease patients on hemodialysis at Can Tho General Hospital. Subjects and method: a cross-sectional descriptive study in 52 end-stage renal disease (ESRD) patients on hemodialysis at Can Tho General hospital, at least 4 weeks after 4th dose of Covid-19 vaccine, from July 2022 to January 2023. Results: men were 50%, the mean age was 51,6±12,9, mean time on hemodialysis was 6,77±3,44 years. All patients with ESRD disease had anti-RBD IgG antibodies after receiving 4 doses of Covid-19 vaccine, the average antibodies concentration was 1237.13±6021.96 AU/mL. Patients with multiple comorbidities had lower antibody levels than the group with 1 comorbidity. Anti-RBD IgG antibody concentrations were much lower in the smokers group than in the non-smokers (8182.0±3720.14 AU/mL vs 13505.0±6052.49 AU/mL, p=0.001). There was a moderate inverse correlation between the anti-RBD IgG antibody levels and the age of the patient (r= -0.32, p=0.03). Conclusions: 4 doses of Covid-19 vaccine have high antibody production efficiency in patients with end-stage renal disease.

Article Details

References

Bộ Y tế (2022), “Hướng dẫn tiêm vắc xin phòng COVID-19”, Công văn số 3309/BYT-DP BYT-DP, Cổng thông tin điện tử moh.gov.vn.
2. Hoàng Lê Trung Hiếu và cộng sự (2022), “Đặc điểm sinh kháng thể trung hòa kháng vùng liên kết thụ thể (RBD) protein gai của SARS-CoV-2 của nhân viên y tế được tiêm ngừa vaccine Covid-19 tại bệnh viện Mỹ Đức, tạp chí Y Học TP. Hồ Chí Minh, Tập 26 (1), tr.8-15.
3. Anastasia P, et al. (2022), “Factors associated with anti-SARS-CoV-2 antibody titres 3 months post-vaccination with the second dose of BNT162b2 vaccine: a longitudinal observational cohort study in western Greece”, BMI Open, 12:e057084.
4. Bonanad C, et al. “The effect of age on mortality in patients with COVID-19: a meta-analysis with 611,583 subjects”, J Am Med Dir Assoc, 21(7), pp.915-918.
5. Borja Quiroga, et al. (2022), “Long-Term Dynamic Humoral Response to SARS-CoV-2 mRNA Vaccines in Patients on Peritoneal Dialysis”, Vaccines, 10, pp.1738.
6. Patrick Affeldt, et al. (2022), “Immune response to third and fourth Covid-19 vaccination in hemodialysis patients and kidney transplant recipients”, Viruses, 14, pp.2646.
7. Paul Martin, et al. (2022), “Comparison of immunogenicity and clinical effectiveness between BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines in people with end-stage kidney disease receiving haemodialysis: A prospective, observational cohort study”, The Lancet Regional Health – Europe, 21, pp.100478.
8. Roengrudee P. and Stanton A. Glantz (2020), “Smoking is associated with Covid-19 progression: A Meta-analysis”, Nicotine & Tobacco Research, 22(9), pp.1653–1656.